XOMA Ltd. (NasdaqGM: XOMA)

[langtubui05]

i was with XOMA from the April 2009. and i was in when it 1.45$. XOMA is a good company for long term. now it can operate untill 2011. good time to get in now. strong buy

[DogDayTrader]

Lets' take a look at the chart.

[mbmalone]

How big is this going to go when the new partner for XOMA 052 is announced? ... hince the current holding pattern. Their most recent clinical trial is being funded by JDRF (Juvenile Diabetes Research Foundation) and being led by Prof. M. Donath in Switzerland, winner of the 2008 Novartis Prize in Diabetes. Bioterrorism Defense & Botulism seem to be in the news a lot these days, with XOMA 3AB currently in development as a field injectable counter agent.

Four of the countries listed by the US government as "state sponsors of terrorism" (Iran, Iraq, North Korea, and Syria) have developed, or are believed to be developing, botulinum toxin as a weapon. XOMA currently has 3 military contracts to develop XOMA 3AB which is designed to neutralize botulinum neurotoxin Type A, which causes paralysis and is expanding it's efforts into 3rd world countries. After the 1991 Persian Gulf War, Iraq admitted to the United Nations inspection team to having produced 19,000 L of concentrated botulinum toxin, of which approximately 10,000 L were loaded into military weapons. These 19,000 L of concentrated toxin are not fully accounted for and constitute approximately 3 times the amount needed to kill the entire current human population by inhalation.

XOMA also develops inject-able forms of highly potent antibodies that can be given at very low doses for mass casualty events. This provides an easier method of administration and several safety advantages compared to currently available therapies which still use legacy technologies such as lower potency animal-derived antibodies given by time-consuming intravenous methods. There is currently no other therapy that can be administered by simple injection in the field. In fact, it's normally a very slow drawn-out process requiring a long hospital stay. You actually die by suffocation due to paralysis.

HHSN266200600008C
HHSN272200800028C
HHSN272200800028C

The stock has been heavily shorted, but the short interest seems to be losing it's grip and is decreasing.
A nice volume surge should effectively nuke the lingering cockroaches and spike the stock to untold heights on the expected big news release.
Short Interest - XOMA Ltd. (XOMA) - NASDAQ.com

This stock seems very undervalued, waaaay oversold.